Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Niu, Qi ^a   Wang, Wei ^a   Li, Yong ^a   Ruden, Douglas M ^b   Wang, Fenghua ^a   Li, Yue ^c   Wang, Fangying ^a   Song, Jingying ^a   Zheng, Kun ^a  

^a No 309 PLA Hospital   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BEIJING CENTER FOR PHYSICAL AND CHEMICAL ANALYSIS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BOPUQIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; LEUPEPTIN; LOW MOLECULAR WEIGHT HEPARIN; MESSENGER RNA; PEPSTATIN; PROTEASOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CARCINOGENICITY; CELL COUNT; CELL CULTURE; CELL FUNCTION; CELL ISOLATION; CELL LEVEL; CELL PROLIFERATION; COLONY FORMING CELL; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIDE POPULATION CELL; TARGET CELL; TREATMENT OUTCOME; TUMOR ABLATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LEUPEPTINS; LUNG NEOPLASMS; MALE; MICE; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEOLYSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864220149     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041035     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA: A Cancer Journal for Clinicians 61: 69-90.
2. Eramo A, Haas TL, De Maria R, (2010) Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 29: 4625-4635.
3. Bonnet D, Dick JE, (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med 3: 730-737.
4. Lessard J, Sauvageau G, (2003) Bmi-1 determined the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260.
5. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 1302-1313.
6. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514.
7. Ma S, Chan KW, Hu L, Lee TK, Wo JY, et al. (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556.
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
9. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumor initiating cells. Nature 432: 396-401.
10. Dean M, Fojo T, Bates S, (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
11. Hirshmann JC, Foster AE, Wulf GG, Nuchtern JG, Jax TW, et al. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. PNAS 101: 14228-14233.
12. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, et al. (2004) Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer Clin. Cancer Res 10: 1691-1697.
13. Alison MR, Lim SM, Nicholson LJ, (2011) Cancer stem cells: problems for therapy? J Pathol 223: 147-161.
14. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, et al. (2010) Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141-3152.
15. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659.
16. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, et al. (2010) Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 13: 109-118.
17. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K, (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507-7511.
18. Mitrovska S, Jovanova S, (2009) Low-molecular weight heparin enoxaparin in the treatment of acute coronary syndromes without ST segment elevation. Bratisl Lek Listy 110: 45-48.
19. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, et al. (1992) Comparison of subcutaneous low-molecularweight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339: 441-445.
20. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Pris MH, et al. (1999) Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82: 947-952.
21. Akl EA, van Doormaal FF, Barba M, Kamath G, Kim SY, et al. (2008) Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. Journal of Experimental & Clinical Cancer Research 27: 4.
22. Thodiyil P, Kakkar AK, (2002) Can low-molecular-weight heparins improve outcome in patients with cancer? Cancer Treat Rev 28: 151-155.
23. Chatzinikolaou G, Nikitovic D, Berdiaki A, Zafiropoulos A, Katonis P, et al. (2010) Heparin regulates colon cancer cell growth through p38 mitogen-activated protein kinase signaling. Cell Prolif 43: 9-18.
24. van Doormaal FF, Nisio MD, Otte HM, Richel DJ, Prins M, et al. (2011) "Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer." J Clin Oncol 29: 2071-2076.
25. Klerk CP, Smorenburg SM, Otten HM, Lensing AWA, Prins MH, et al. (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23: 2130-2135.
26. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA, (2007) The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5: 729-737.
27. Schulman S, (2005) Hypercoagulability preceding cancer. Are anticoagulants also antineoplastic? J Thromb Haemost 3, 581-583.
28. Icli F, Akbulut H, Utkan G, Yalcin B, Dincol D, et al. (2007) Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 95: 507-512.
29. Angelini A, Ciofani G, Baccante G, Di Febbo C, Carmine Di Cuccurullo F, et al. (2007) Modulatory effects of heparin on cellular accumulation and cytotoxicity of doxorubicin in MRP1-overexpressing HL60/doxo cells. Anticancer Res 27: 351-355.
30. Maia RC, Wagner K, Cabral RH, Rumjanek VM, (1996) Heparin reverses Rhodamine 123 extrusion by multidrug resistant cells. Cancer Lett 106: 101-108.
31. Phillips PG, Yalcin M, Cui H, Abdel-Nabi H, Sajjad M, et al. (2011) Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res 31: 411-419.
32. Niers TM, Klerk CP, DiNisio M, Van Noorden CJF, Büllerc HR, et al. (2007) Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 61(3): 195-207.
33. Smorenburg SM, Van Noorden CJ, (2001) The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53(1): 93-105.
34. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, et al. (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. Journal of thrombosis and haemostasis 2: 1266-1271.
35. Teng Y, Wang X, Ma D, (2010) wntβ-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochemical and biophysical research communications 392: 373-379.
36. Elsaba TMA, Martinez-Pomares L, Robins AR, Crook S, Seth R, et al. (2010) The Stem Cell Marker CD133 Associates with Enhanced Colony Formation and Cell Motility in Colorectal Cancer. 5(5): e10714.